Sugi Predict

Sugi Predict / Compounds / SCHEMBL30891277

SCHEMBL30891277

SCHEMBL30891277

O=C(CC[C@H](NC(=O)OCc1ccccc1)C(=O)NCCCCCC(=O)N(CCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)CCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)NCCCCCC(=O)N(CCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)CCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.55

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 10/20 0.51
▸ TPSAB1 Q15661 2/20 0.45
▸ SIRT1 Q96EB6 8/20 0.44
▸ SIRT3 Q9NTG7 7/20 0.44
▸ PTGER4 P35408 3/20 0.43
▸ CAPN1 P07384 1/20 0.42
▸ CAPN2 P17655 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891492 0.96 SIRT2 (0.51) SIRT2TPSAB1SIRT1SIRT3PTGER4
SCHEMBL30891417 0.89 SIRT2 (0.56) SIRT2TPSAB1SIRT1SIRT3PTGER4
SCHEMBL30891438 0.88 HTT (0.43) PTGER4
SCHEMBL25437088 0.88 PTGER4 (0.47) SIRT2SIRT1SIRT3PTGER4
SCHEMBL30891431 0.87 SIRT2 (0.50) SIRT2TPSAB1SIRT1SIRT3PTGER4
SCHEMBL30891346 0.87 SIRT2 (0.46) SIRT2TPSAB1SIRT1CAPN1CAPN2
SCHEMBL30391841 0.87 SIRT2 (0.43) SIRT2SIRT1SIRT3PTGER4CAPN1
SCHEMBL22750081 0.86 SIRT2 (0.43) SIRT2TPSAB1PTGER4
SCHEMBL23575261 0.86 SIRT2 (0.43) SIRT2TPSAB1PTGER4
SCHEMBL30891269 0.86 SIRT2 (0.42) SIRT2TPSAB1SIRT1SIRT3PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2026-01-22 — — US disclosed
EP-4615487-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2025-09-17 — — EP disclosed
WO-2024102633-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2024-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES INSR, GPR119, GLP1R SIRT2 836/4885TPSAB1 807/4885SIRT1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback